SuperBranche

Executive Summary

SuperBranche is a French biotechnology company pioneering a proprietary magnetic nanoparticle platform (SUPERSPIO) for in vivo cancer imaging and therapy. Its technology uniquely combines non-ionizing MRI, quantitative MPI, and targeted magnetic hyperthermia in a single theranostic approach, addressing key limitations in current cancer diagnostics and treatment. The company is initially focusing on solid tumors, with its lead candidate designed to enable precise tumor localization and localized heat therapy, potentially reducing systemic side effects. The platform's versatility also positions it for broader applications in oncology and beyond. SuperBranche is advancing its lead candidate toward clinical trials and is building a GMP-compliant pilot plant to manufacture its nanoparticles at scale, a critical step for regulatory filings and commercialization. While still in the preclinical stage, the company has established a strong intellectual property position and shown promising proof-of-concept data. The upcoming milestones—completion of the GMP facility, IND/CTA submission, and initial clinical data—will be key to de-risking the platform and unlocking value. Given the innovative nature of the technology and the large unmet need in solid tumor treatment, SuperBranche represents an attractive opportunity, though execution risk remains moderate.

Upcoming Catalysts (preview)

• Q4 2026Completion of GMP Pilot Plant90% success
• H1 2027IND/CTA Submission for Lead Candidate60% success
• Q2 2027Initial Preclinical Efficacy Data in Solid Tumor Models75% success